Comprehensive set of fixed price analyses and custom recommendations maximize opportunity for vendors to exploit WandA expertise
June 15, 2009 (Needham, MA) -- Waife and Associates, Inc. (WandA), change management consultants for biopharmaceutical clinical research, announced today, in advance of the Drug Information Association Annual Meeting, a new set of packaged services for the software and service vendors supporting the clinical research industry. WandA will analyze a broad range of a vendor’s strategy and operations, provide a gap analysis, observations and recommendations, and answer specific questions vendors have in response. Examples of the analyses’ breadth include business strategy, operational resourcing, organizational structure, financial targets, metrics, product marketability, support quality, audit readiness, and similar topics. Vendors who can benefit from this package include clinical research IT vendors, software services, CROs, niche service providers such as early stage or periapproval service providers, and large investigative sites or academic research providers.
Waife and Associates has long provided consulting support to clinical research vendors as an ancillary part of its primary business of providing process consulting to research sponsors. Such support has been pivotal for the launching of many industry vendors, but can be provided more efficiently and more broadly. As a consequence, this new package service is designed to ensure that when WandA and a vendor agree to work together, that sufficient and comprehensive individualized advice can be provided at an efficient price point. The package ensures confidential consulting from the industry’s experts on vendor strategy and performance, and enables vendors to work with the full range of WandA Associates, as required.
“WandA has analyzed its myriad experiences in helping vendors better perform in support of our clinical research clients,” said Ronald S. Waife, President of Waife and Associates, Inc. “It is clear to us that those vendors do best when seeking consulting if they have their businesses fully analyzed, something many vendors are not likely to do because of concerns about cost. As a consequence, we have designed an approach to comprehensive analysis that enables us to provide this consulting at a price point we expect most vendors can absorb. This is a quid pro quo – vendors who use this service need to be open to a broad-based analysis which will provide them the greatest, integrative, benefit.”
As Mr. Waife added, “Our primary goal in helping vendor performance is to help research sponsors, who are increasingly reliant on these vendors, improve the likelihood that these vendors are prepared to perform with operational excellence, efficiency, and stability.”
For a confidential conversation about pricing and scheduling of this new Clinical Research Vendor Support package, principal managers should contact info@waife.com.
|
|
